Brilliant Shady....
Another way of looking at what is very real (non) "efficient market" problem...
I tend to be more of a purist (as you probably know by now) in terms of considering dilution as simply the "% stake you hold of the business before and after the CR": (hence my "a biotech shareholder should really be looking at their investment as if they were a venture capitalist" model) but sure - Bloody brilliant appraisal.
Loved it. (we need to meet up one day)
On the effects of dilutive capital raisings, page-3
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $323.4M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 276 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |